Skip to main content

USO DE LA INHIBICIÓN DE MYC PARA SUPERAR LA RESISTENCIA A LA INMUNOTERAPIA EN NSCLC IMPULSADO POR KRAS CON DIVERSOS PERFILES MUTACIONALES (MYCOMBIO)

PLEC2021-007959

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i en Líneas Estratégicas
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre PEPTOMYC SL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MYC and KRAS cooperation, from historical challenges to therapeutic opportunities in cancer

  • Casacuberta-Serra, Sílvia|||0000-0002-2595-1115
  • González-Larreategui, Íñigo|||0000-0002-0959-8497
  • Capitán-Leo, Daniel
  • Soucek, Laura|||0000-0002-4750-7971
RAS and MYC rank amongst the most commonly altered oncogenes in cancer, with RAS being the most frequently mutated and MYC the most amplified. The cooperative interplay between RAS and MYC constitutes a complex and multifaceted phenomenon, profoundly influencing tumor development. Together and individually, these two oncogenes regulate most, if not all, hallmarks of cancer, including cell death escape, replicative immortality, tumor-associated angiogenesis, cell invasion and metastasis, metabolic adaptation, and immune evasion. Due to their frequent alteration and role in tumorigenesis, MYC and RAS emerge as highly appealing targets in cancer therapy. However, due to their complex nature, both oncogenes have been long considered "undruggable" and, until recently, no drugs directly targeting them had reached the clinic. This review aims to shed light on their complex partnership, with special attention to their active collaboration in fostering an immunosuppressive milieu and driving immunotherapeutic resistance in cancer. Within this review, we also present an update on the different inhibitors targeting RAS and MYC currently undergoing clinical trials, along with their clinical outcomes and the different combination strategies being explored to overcome drug resistance. This recent clinical development suggests a paradigm shift in the long-standing belief of RAS and MYC "undruggability", hinting at a new era in their therapeutic targeting.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer

  • Giuntini, Fabio
  • González-Larreategui, Íñigo|||0000-0002-0959-8497
  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Casacuberta-Serra, Sílvia|||0000-0002-2595-1115
  • Zacarías-Fluck, Mariano F.|||0000-0002-7171-4268
  • Arnal, Magdalena|||0000-0001-8647-9232
  • Pedretti, Flaminia
  • Martínez-Martín, Sandra|||0000-0003-4443-0697
  • Thabussot, Hugo
  • Cano, Virginia Castillo
  • Grueso, Judit|||0000-0003-1093-7940
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Serrano, Erika
  • López-Estévez, Sergio|||0000-0001-5355-8073
  • Rodriguez, Olga
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodriguez-Hernandez, Adela
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Nonell, Lara|||0000-0002-8538-8213
  • Prat, Aleix|||0000-0003-2377-540X
  • Serra, Violeta|||0000-0001-6620-1065
  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Soucek, Laura|||0000-0002-4750-7971
MYC is dysregulated in most human cancers and is a DNA damage response (DDR) modulator capable of both promoting genomic instability and enhancing DNA repair. Here, we show that Omomyc, the only direct MYC inhibitor that has completed a phase 1 trial, shuts down DDR genes in triple-negative breast cancer (TNBC), causing DDR defects and inducing DNA damage. Since DDR-deficient tumors are currently targeted by poly ADP-ribose polymerase inhibitors (PARPis), we tested combinations with Omomyc. We show that Omomyc-induced DNA damage is enhanced by PARPis and that the inhibitors cooperate even in models with intrinsic or acquired PARPi resistance, both in vitro and in vivo. Moreover, using patient-derived models and clinical samples, we reveal a role for MYC as a predictor of PARPi resistance. Overall, our research highlights the opportunity of combining MYC inhibition by Omomyc with PARPis in PARPi-resistant TNBC, where MYC transcriptional activity represents a predictive biomarker of resistance to therapy.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

  • Giuntini, Fabio
  • Massó-Vallés, Daniel
  • Whitfield, Jonathan
  • Soucek, Laura
DNA damage response; DNA damage response inhibitors; MYC inhibition, Respuesta al daño del ADN; Inhibidores de la respuesta al daño del ADN; Inhibición de MYC, Resposta al dany de l'ADN; Inhibidors de la resposta al dany de l'ADN; Inhibició de MYC, MYC performs a dual role in DNA Damage Response (DDR), promoting genomic instability through replication stress, R-loop formation, and topoisomerase-mediated damage, while simultaneously activating DNA repair pathways to maintain cell survival. This review provides a comprehensive analysis of how MYC inhibition affects DDR pathway dependencies. In fact, when MYC is inhibited, cancer cells lose both their proficient DNA repair capacity and their protective mechanisms against replication stress. This creates a therapeutic window in which combining MYC inhibitors with DDR-targeting agents may achieve synergistic anti-cancer effects. Central to this approach is the exploration of rational combination strategies that pair MYC inhibitors with various DDR modulators including Poly (ADP-ribose) polymerase (PARP) inhibitors, ATR/CHK1 inhibitors, and other DNA repair pathway disruptors. This review summarizes preclinical evidence demonstrating enhanced therapeutic efficacy when MYC inhibition is combined with DDR-targeting agents and discusses early clinical findings that support this promising therapeutic strategy., The author(s) declared that financial support was received for this work and/or its publication. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – FG PFIS doctoral bursary), Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1, Líneas Estratégicas PLEC2021-007959), Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509), EDIReX (H2020 INFRAIA 731105-2), the European Research Council (ERC-2023-ADG 101142260), the Spanish Ministry of Science and Innovation and European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808) and the FERO foundation for funding support.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

  • Giuntini, Fabio
  • Massó-Vallés, Daniel
  • Whitfield, Jonathan
  • Soucek, Laura
DNA damage response; DNA damage response inhibitors; MYC inhibition, Respuesta al daño del ADN; Inhibidores de la respuesta al daño del ADN; Inhibición de MYC, Resposta al dany de l'ADN; Inhibidors de la resposta al dany de l'ADN; Inhibició de MYC, MYC performs a dual role in DNA Damage Response (DDR), promoting genomic instability through replication stress, R-loop formation, and topoisomerase-mediated damage, while simultaneously activating DNA repair pathways to maintain cell survival. This review provides a comprehensive analysis of how MYC inhibition affects DDR pathway dependencies. In fact, when MYC is inhibited, cancer cells lose both their proficient DNA repair capacity and their protective mechanisms against replication stress. This creates a therapeutic window in which combining MYC inhibitors with DDR-targeting agents may achieve synergistic anti-cancer effects. Central to this approach is the exploration of rational combination strategies that pair MYC inhibitors with various DDR modulators including Poly (ADP-ribose) polymerase (PARP) inhibitors, ATR/CHK1 inhibitors, and other DNA repair pathway disruptors. This review summarizes preclinical evidence demonstrating enhanced therapeutic efficacy when MYC inhibition is combined with DDR-targeting agents and discusses early clinical findings that support this promising therapeutic strategy., The author(s) declared that financial support was received for this work and/or its publication. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – FG PFIS doctoral bursary), Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1, Líneas Estratégicas PLEC2021-007959), Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509), EDIReX (H2020 INFRAIA 731105-2), the European Research Council (ERC-2023-ADG 101142260), the Spanish Ministry of Science and Innovation and European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808) and the FERO foundation for funding support.